Naslov
Agents acting on the renin-angiotensin system: usage in Croatia during a seven-year period

Autori
Vitezić, Dinko ; Matana Kaštelan, Zrinka ; Buble, Tonći ; Vitezić Miomira ; Kovačević Miljenko ; Mršić Pelčić, Jasenka ; Župan, Gordana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Value in Health / - , 2009, 343-343

Skup
Twelfth Annual European Congress of International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Mjesto i datum
Pariz, Francuska, 24.10.2009. - 27.10.2009

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
cardiovascular diseases; drugs acting on renin-angiotensin system; drugs usage; seven-year period

Sažetak
Introduction In the contemporary world, particularly in developing countries, cardiovascular (CV) diseases are a major health care problem. CV and cerebrovascular diseases were the cause of over 50% of deaths in Croatia in 2004. Adequate therapy of these diseases, which includes usage of drugs acting on renin-angiotensin system (RAS), leads to reduction of CV and cerebrovascular morbidity and mortality. These drugs are used in management of variety of cardiovascular disorders and established their significance in hypertension, heart failure, stoke prevention, managing asymptomatic and symptomatic left-ventricular dysfunction, and diabetes. Prescribing of ACE inhibitor group in the treatment of hypertension during the last decade is among the highest in general (family) practice. The aim of our study was to identify and analyze changes in the use of drugs acting on RAS in Croatia during the seven-year period (2001-2007). Methods The data concerning drugs usage prescribed by GPs during the period from 2001 to 2007 were collected from the Croatian Health Insurance Institute (CHII). CHII maintains a database on drugs prescribed by primary health care physicians and dispensed by pharmacies. This database does not include non-prescription drugs, drugs paid by patients or in-hospital used drugs. According to the World Health Organization Collaborating Centre for Drugs Statistics Methodology annual volumes of drugs are presented in defined daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data are presented in Euros (€). An average cost per DDD was calculated for this group of drugs. Results Agents acting on the RAS for the seven-year period remained the most prescribed CV drug group with the largest cost share. The use of the whole group increased 115% (from 56.07 to 120.55 DDD/1000) while the related expenses increased 53.5%. The consumption and cost shares of ACE inhibitors (plain and combined) decreased (from 98% to 88% and from 96% to 90%, respectively). The use of the combinations of ACE inhibitors and diuretics increased from 10.07 to 41.90 DDD/1000 and angiotensin receptor blockers and diuretics from 0 to 6.42 DDD/1000. The average cost per DDD for the investigated group dropped from 0.33 to 0.24 €/DDD. Conclusion During the investigated period the usage of the group of agents acting on the RAS increased considerably. The related growth of financial expenditure increased at a slower rate. The average cost per DDD gradually decreased mainly as the result of the introduction of generics and the implementation of restrictive measures on the Croatian drug market.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA